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Abstract
Background: High density cDNA microarray technology provides a powerful tool to survey the
activity of thousands of genes in normal and diseased cells, which helps us both to understand the
molecular basis of the disease and to identify potential targets for therapeutic intervention. The
promise of this technology has been hampered by the large amount of biological material required
for the experiments (more than 50 µg of total RNA per array). We have modified an amplification
procedure that requires only 1 µg of total RNA. Analyses of the results showed that most genes
that were detected as expressed or differentially expressed using the regular protocol were also
detected using the amplification protocol. In addition, many genes that were undetected or weakly
detected using the regular protocol were clearly detected using the amplification protocol. We
have carried out a series of confirmation studies by northern blotting, western blotting, and
immunohistochemistry assays.
Results: Our results showed that most of the new information revealed by the amplification
protocol represents real gene activity in the cells.
Conclusion: We have confirmed a powerful and consistent cDNA microarray procedure that can
be used to study minute amounts of biological tissue.
Background
Cancer is a progressive genetic disease that involves the ac-
cumulation of multiple and heterogeneous genetic and
epigenetic changes. Among the 30,000 – 40,000 human
genes [1,2], an expanding list of genes has been shown to
be involved in cancer development and progression. Re-
cently developed technologies, including cDNA microar-
rays, allow cancer researchers to screen thousands of genes
simultaneously to identify genes that show abnormal ex-
pression in cancers [3–6].
Cancer researchers face a serious challenge when trying to
apply these tools to clinical cancer specimens. First, can-
cers are often detected at a late stage in development, after
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the cancer metastatic and highly refractory even to harsh
treatment. Multiple clones in the same tumor mass, which
can often be distinguished by morphological features,
would yield more information if they could be microdis-
sected and analyzed separately. Second, tumor tissues in-
variably include a mixture of different cells, such as
inflammatory cells, stromal cells, vascular cells, and oth-
ers. Each type of cells may contribute to a unique aspect of
the cancer phenotype and may serve as a target for treat-
ment. Therefore, there is a need to dissect those cells for
separate study. For example, it was found that tumor vas-
cular cells have distinct gene expression profiles from
those of normal vascular cells [7], and the genes that are
uniquely expressed on the surface of tumor endothelium
cells can serve as targets for specific cancer therapy. Final-
ly, a key breakthrough in cancer treatment would come
from early detection and diagnosis of cancer and the study
of molecular events in the early stages of cancer progres-
sion. A difficulty in studying cancer at early stages is that
the tumor size is small and only limited material can be
obtained through means such as fine needle aspiration.
Identification of the genetic changes in such a small sam-
ple is especially challenging because only limited assays
can be performed using conventional approaches. It is ob-
vious that the full potential of genomic technologies will
only be realized if they can be applied to minute amounts
of biological material.
For a typical gene expression profiling experiment carried
out on a glass microarray where thousands of cDNA
probes are deposited in an orderly manner, RNA is first
isolated from the biological material under study. The
mRNA (1–5% of total RNA) is reverse transcribed to cD-
NA, during which process fluorescent dyes (Cy3 or Cy5)
are incorporated. The labeled cDNAs are hybridized to the
microarray and, after washing, the fluorescent signals are
detected by a laser scanner. Current protocols typically re-
quire more than 50 µg of total RNA for consistent micro-
array hybridization. Several hundred milligrams of tumor
tissues are often needed to obtain this much RNA, which
is simply unavailable in many situations. Thus, it is crucial
to develop a more sensitive and reliable procedure that re-
quires less RNA. Several molecular biology approaches,
such as T7 in vitro transcription and PCR based assays,
have been attempted [8–10]. However, only cursory anal-
ysis has been carried out to validate the assays, and limit-
ed confirmation experiments have been performed to
evaluate the validity of the amplification results.
In this study, we performed and analyzed a set of nine
microarray experiments to evaluate an amplification pro-
tocol adopted from Wang et al[9]. Focusing primarily on
the ability to identify differentially expressed genes, we
developed the following criteria for a successful amplifica-
tion protocol:
1. Because amplification may enhance the signal of genes
expressed at low copy numbers, more genes should be de-
tected by an amplification protocol than by a regular pro-
tocol.
2. Most genes detected as differentially expressed using a
regular protocol should also be detected using an amplifi-
cation protocol. In other words, the two protocols should
reveal similar patterns of differential expression.
3. An amplification protocol should generate signal inten-
sity profiles as reproducibly and reliably as a regular pro-
tocol.
4. Microarray results obtained from an amplification pro-
tocol should match data obtained from other molecular
biology approaches such as northern blotting, western
blotting and immunohistochemistry assay.
Our results showed that our amplification protocol pro-
duced reproducible, reliable microarray data that was con-
sistent with the regular protocol. We also confirmed that
our amplification protocol revealed accurate information
about the differential expression of low copy number
genes that failed to give sufficient signal intensities using
the regular protocol. Therefore, many clinical experiments
for which only a minute amount of material is available
can be pursued using this protocol.
Results
A total of nine microarray experiments were performed
(yielding 18 images). Among the nine experiments, five
used the regular protocol with varying amounts of total
RNA (100 µg to 300 µg) and four used the amplification
protocol with 1.0 µg total RNA. Each experiment com-
pared U251 (in the Cy5 channel) with LN229 (in the Cy3
channel). Detailed information about the experiments is
provided in Table 1. We evaluated the amplification pro-
tocol using the criteria described earlier.
Enhancement of signal intensity for genes expressed at a 
low copy number
We expected the amplification protocol to increase the
signal intensity of low expressing genes; in other words,
the number of genes having measurable signal intensity
above background levels from using the amplification
protocol should be higher than that using the regular pro-
tocol. We used S/N > 2.0 to determine if a gene has meas-
urable signal intensity on an array; i.e., if the difference
between signal intensity and background intensity is
greater than 2.0 SD of the local background, then the gene
gives adequate signal intensity. We assessed all 9 arrays;Page 2 of 8
(page number not for citation purposes)
BMC Genomics 2002, 3 http://www.biomedcentral.com/1471-2164/3/16the results are summarized in Table 2. The results showed
that the number of genes whose S/N ratio exceeds 2 SD of
background is consistently higher in both channels when
using the amplification protocol. The signal intensities of
low expressors, indeed, are improved so that more genes
turned out to be detectable. Our result also showed that
the PCR step (1 or 3 cycles) before aRNA amplification
had no detectable effect on the final results.
Consistent patterns of differential gene expression
Finding differentially expressed genes is one of the goals
of microarray technology. Ideally, both the regular and
amplification protocols would identify the same list of
differentially expressed genes. We did not expect to see
identical lists of differentially expressed genes generated
from the two protocols, since we may not even achieve
that goal using the same protocol twice due to the varia-
bility associated with microarray experiments [12–14].
However, we do want to see most differentially expressed
genes appearing on both lists.
To identify differentially expressed genes, we computed
"smooth t-statistics". To apply this method, we first com-
puted the mean log intensity and the standard deviation
for the replicated spots within each channel. Since the
standard deviation varies systematically with the mean,
we then fit a smooth curve representing the standard devi-
ation as a function of the mean. After pooling the smooth
estimates of standard deviation from the two channels, we
used the pooled estimates to compute a t-statistic for each
gene [13,15]. These "smooth t-statistics" can also be
viewed as "studentized log ratios"; i.e., as log ratios be-
tween channels that have been rescaled to account for the
intrinsic variability.
We found that the consistency and reproducibility of
smooth t-statistics between experiments is high regardless
of the protocol being used. We quantified the reproduci-
bility using the concordance coefficient, which is analo-
gous to the correlation coefficient but measures how well
a set of points matches the identity line [16–18]. The con-
Table 1: Array Information
Array ID Cy5 Channel Cy3 Channel Description
R1 U251 LN229 Regular protocol, using 300 µg total RNA
R2 U251 LN229 Regular protocol, using 200 µg total RNA
R3 U251 LN229 Regular protocol, using 100 µg total RNA
R4 U251 LN229 Regular protocol, using 100 µg total RNA
R5 U251 LN229 Regular protocol, using 100 µg total RNA
A6 U251 LN229 Amplification protocol, using 1 µg total RNA, 3 cycles of 
PCR
A7 U251 LN229 Amplification protocol, using 1 µg total RNA, 3 cycles of 
PCR
A8 U251 LN229 Amplification protocol, using 1 µg total RNA, 1 cycle of PCR
A9 U251 LN229 Amplification protocol, using 1 µg total RNA, 1 cycle of PCR
Table 2: Number of Genes(of 2304 Genes) with S/N > 2
Array Cy5 Channel Cy3 Channel
R1 1796 (78.0%) 1801 (78.2%)
R2 960 (41.7%) 1784 (77.4%)
R3 387 (16.8%) 1112 (48.3%)
R4 268 (11.6%) 883 (38.3%)
R5 284 (12.3%) 955 (41.4%)
A6 2097 (91.0%) 1988 (86.3%)
A7 1990 (86.4%) 1729 (75.0%)
A8 1814 (78.7%) 1738 (75.4%)
A9 2038 (88.5%) 1815 (78.8%)
Arrays R1 – R5 were produced using the regular protocol. Arrays A6 – A9 were produced using the amplification protocol.Page 3 of 8
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ranged from 0.574 to 0.835, with a median of 0.739. The
concordance using the amplification protocol ranged
from 0.843 to 0.894, with a median of 0.873. The con-
cordance between the experiments using different proto-
cols ranged from 0.562 to 0.796, with a median of 0.652.
Using data from all experiments performed with the regu-
lar protocol, we computed a combined set of smooth t-
statistics. We computed a similar set of t-statistics using
data from all experiments performed with the amplifica-
tion protocol. Genes are viewed as differentially expressed
if the smooth t-statistic exceeds some threshold; for this
study, we chose genes with smooth t-statistic greater than
four in absolute value. Using this criterion, we found that
the regular protocol identified 21 genes that were differen-
tially expressed between U251 and LN229 cell lines, and
the amplification protocol identified 28 differentially ex-
pressed genes. Fifteen genes were common to both lists.
Thirteen genes were found using the amplification proto-
col but not the regular protocol; the smooth t-statistics for
these genes ranged in absolute value from 1.19 to 3.96,
with a median of 2.23. Six genes were found using the reg-
ular protocol but not the amplification protocol; the
smooth t-statistics for these genes using the amplification
protocol ranged in absolute value from 3.16 to 3.97 with
a median of 3.42. In every case, the sign of the t-scores was
the same using the different protocols, indicating that the
same cell line overexpressed the gene.
Reproducibility and reliability of signal intensity
To evaluate whether the amplification protocol preserved
signals that were seen using the regular protocol, we first
found all the spots in each channel (U251 or LN229) that
consistently had S/N > 2.0 in all five experiments using
the regular protocol. We then computed the percentage of
those genes that also had S/N > 2.0 on each of the arrays
using the amplification protocol. We found that 95% to
100% of the genes that are consistently found to be ex-
pressed using the regular protocol were also found to be
expressed using the amplification protocol. For U251 on
four amplified arrays, the percentages are 100%, 99%,
98%, and 100%; for LN229, 100%, 96%, 95%, and 98%.
Confirmation of the results from amplification experi-
ments
A key criterion for the validity of microarray experiments
is whether the results are real and can be confirmed by
other approaches. In order to obtain representative infor-
mation rather than noise from nonspecific binding of tar-
gets to the DNA probes in a microarray experiment, the
hybridization has to be specific. To demonstrate the hy-
bridization specificity in our microarray experiments, we
selectively labeled a specific target such as actin or GAPDH
with one dye and hybridized to the microarray. Our re-
sults showed that the specific target only hybridized to its
corresponding spots on the array [19]. Second, in order to
confirm the results, the clones printed on the microarray
have to be correct and error free. This is an important issue
because most clone libraries used for making microarrays
Figure 1
Composite array images generated by the amplification protocol. The labeled cDNA probes were generated from
total RNA from the U251 cell line (Cy5) and the LN229 cell line (Cy3), respectively. Seven differentially expressed genes were
randomly picked up across the array. Among these, four genes, GFAP, S100, HLA-DR and SNRP-B, were detected by using
both the amplification and the regular protocols; three genes, IGFBP2, integrin beta 4 and HLA-A, were detected only using the
amplification protocol.Page 4 of 8
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the clones printed on our microarrays were sequence ver-
ified before printing [20]. Because of those quality control
measures, we expected that our microarray results should
be confirmed as long as the amplification is stable and
consistent among different experiments.
From the results of comparison between U251 and
LN229, we selected six genes that showed differential ex-
pression either using both the regular and the amplifica-
tion procedures or only using the amplification
procedure. Among these, four genes were detected by both
protocols and two genes were only detected by the ampli-
fication protocol (Figure 1). Genes that belong to the lat-
ter case are most likely expressed at very low levels that fall
below the threshold of detection by the regular protocol.
These genes were then tested by other molecular method-
ologies.
We first selected two genes, S100 and GFAP, that are com-
mon markers for glial cells. Among U251 and LN229
cells, the microarray results from both protocols showed
that S100 was expressed at higher levels in LN229 cells
and GFAP at higher levels in U251 cells. U251 and LN229
cells were embedded in paraffin blocks and sectioned. The
sections were stained with antibodies for those two anti-
gens. The immunohistochemistry results showed that
S100 is expressed at higher levels in LN229 cells and GFAP
at higher levels in U251 cells (Fig 2A). Two additional
genes, HLA-DR alpha and SNRP-B, that were also ob-
tained using the two protocols, were confirmed by north-
ern blotting (Fig 2A).
We mentioned that some low-expressing genes could only
be detected by the amplification protocol and not by the
regular protocol. To confirm whether the new informa-
tion by this approach is reliable, we randomly picked up
two differentially expressed genes, IGFBP2 and integrin
beta 4, that were identified by the amplification protocol
but not by the regular protocol for confirmation using
western blotting, northern blotting and immunohisto-
chemistry assays. The results from these experiments
showed that all the two genes were expressed at higher lev-
els in U251 cells (Figure 2B) as obtained by the microar-
ray data. It should be noted that for the low expressed
genes that could only be detected by the amplification
protocol, longer exposure time for the northern blotting is
needed and the signal intensity is much lower than that
generated from the high expressed genes that could be de-
tected by both protocols (Figure 2B).
In summary, we have carried out a series of confirmation
experiments using northern blotting, western blotting and
immunohistochemistry assay and all six differentially ex-
pressed genes revealed from the microarray experiments
have been confirmed.
Discussion
A major difficulty in the study of cancer is that cancer cells
are extremely elusive and the genetic mutation events are
continuously occurring temporally and spatially. The de-
velopment of high throughput genomic technologies en-
ables us to screen thousands of genes simultaneously for
the informative genes, yet the power of these technologies
is greatly attenuated when inappropriate samples are stud-
ied. Generally speaking, the most biologically appropriate
materials obtained from clinical samples are small in
quantity. This observation motivates the development of
experimental protocols that allow application of genomic
technologies to minute amounts of biological materials.
In this manuscript, we have described such a method that
allows us to use cDNA microarrays with only 1 microgram
of total RNA.
The initial evaluation of the methodology is based on the
detection of fluorescent signals on the microarray after hy-
bridization. Although we could see bright spots with the
amplification protocols, this apparent "success" does not
mean the information so acquired is reliable. False posi-
tives are often the result of side-effects during amplifica-
tion. We set out to assess the accuracy and reliability using
both statistical and experimental approaches. Both ap-
proaches supported the validity of our protocol in the
identification of differentially expressed genes in two cell
populations. This demonstrates that the same genes are
amplified to the same extent in different cell populations.
However, in our results, the amount of amplification var-
ies from gene to gene. Therefore, the amplification process
is not balanced and changes the relative transcript levels
in a given cell population. Thus, from the amplified re-
sults, one cannot infer the relative expression levels of dif-
ferent genes in a single sample. However, in most
biological studies, identification of differentially ex-
pressed genes among different samples is the main aim.
These genes can serve as useful markers for diagnosis, for
prediction of therapeutic response, and perhaps as a target
for developing new drugs. Thus, we have developed an as-
say that will enable us to approach a series of important
clinical issues given a limited amount of material. This as-
say has been used in several ongoing studies and useful in-
formation has been obtained.
Conclusion
We have confirmed a powerful and consistent cDNA
microarray procedure that can be used to study minute
amounts of biological tissue.Page 5 of 8
(page number not for citation purposes)
BMC Genomics 2002, 3 http://www.biomedcentral.com/1471-2164/3/16Materials and Methods
Microarray production
A total of 2,304 known human cDNAs were prepared by
PCR from the Research Genetics cDNA clone library using
the two primers on the vector. The sequences of the two
primers are: up-stream 5'-CTGCAAGGCATTAAGTTGGG-
TAAC-3'; down-stream, 5'- GTGAGCGGATAACAATT-
TCACACAGGAAACAGC-3'. The PCR products were
purified using MultiScreen PCR plates (Millipore Corp.,
Bedford, MA) and verified by sequencing at our Cancer
Figure 2
Confirmation of microarray results. To validate the microarray results seven differentially expressed genes between
LN229 and U251 cell lines were selected across the array. (A) Four differentially expressed genes detected using both the
amplification and the regular protocols were confirmed by immunochemistry assay (GFAP and S100, positive cells are stained
brown) and northern blotting (HLA-DR and SNRP-B). (B) Three other differentially expressed genes, IGFBP2 and integrin beta
4 detected only using the amplification protocol were confirmed by immunohistochemistry assay (IGFBP2), western blotting
(IGFBP2) and northern blotting (integrin beta 4).Page 6 of 8
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394-well plates, were spotted onto poly-L-lysine-coated
microscope slides using a robotic arrayer (Genomic Solu-
tions, Ann Arbor, Michigan). All the clones except for the
control genes such as GAPDH, β-actin, tubulin and an EST
highly similar to GAPDH, are duplicated on the array. Af-
ter printing, the slides are dried, cross-linked by UV (650
J/cm2), washed by water, and stored dry.
RNA amplification and target labeling
U251 and LN229 human glioma cell lines were main-
tained in DMEM supplemented with 10% fetal calf serum
(Gibco-BRL, Gaithersburg, MD). Total RNA was isolated
using TRI reagent (MRC, Cincinnati, OH). 5-Amino-prop-
argyl-2'-deoxycytidine 5'-triphosphate coupled to Cy3
(Cy5) fluorescent dye – Cy 3-AP3-dCTP or Cy5 -AP3-
dCTP (Cy3 and Cy5) were purchased from Amersham
Pharmacia Biotech Inc. (Piscataway, NJ). Reverse tran-
scription was carried out in a 20 µl volume containing 1
µg total RNA, 1 µg oligdT25- T7 (5'-
AAACGACGGCCAGTGAATTGTAATACGACTCACTAT-
AGGG -CGATT-3') primer, 1 µg template switch primer
(5'-AAGCAGTGGTAACAACGC -AGGGACCGGG-3'), 4 µl
first-strand reaction buffer, 2 µl 10 mM dithiothreitol
(DTT; Gibco-BRL) 1 µl 10 mM dNTPs, 1 µl SUPERase-in,
(Amtion, Austin, TX) and 200 u Superscript II reverse tran-
scriptase (Gibco- BRL). cDNA synthesis was completed at
42°C for 2 hours. Then 1 u RNase H (Roche, Branchburg,
NJ) was added to the reaction followed by incubation at
37°C for 15 min. Full-length ds-cDNA was synthesized by
adding 57 µl nuclease-free water, 10 µl 10× PCR buffer
(Roche), 10 µl 25 mM MgCl2, 1 µl 10 mM dNTP and 5 u
Ampli-Taq Gold DNA Polymerase (Roche). The reaction
was carried out at 95°C for 10 min and then 1 or 3 cycles
at: 95°C for 1 min., 65°C for 6 min. A prolonged elonga-
tion time up to 12 min was used in the final cycle. The
PCR product was purified by QIAquick PCR Purification
Kit (Qiagen, Valencia, CA). The anti-sense RNA (aRNA)
amplification by T7 in vitro transcription was carried out
using MEGAscript T7 Kit (Ambion Inc., Austin, TX) fol-
lowing the manufacturer's instructions. After RNA ampli-
fication, the DNA template was removed by incubation of
the reaction with 4 units of RNase-free DNase I (Ambion)
at 37°C for 15 min. aRNA purification was achieved by
Rneasy Mini Kit (Qiagen). The purified 5 µg aRNA was la-
beled with Cy3 or Cy5 by reverse transcription in a solu-
tion containing 10 µg of random hexamer, 4 µl first-
strand reaction buffer, 2 µl 10 mM dithiothreitol (DTT;
Gibco-BRL), 1 µl of 2 mM dATP, dGTP, dTTP and 1 mM
dCTP, 1 µl SUPERase-in, (Amtion) and 200 u Superscript
II reverse transcriptase (Gibco-BRL). The labeling was
completed at 42°C for 2 hours. Then the labeled cDNA
was purified using MicroSpin G-50 columns (Amersham
Pharmacia). The volume was reduced to about 10 µl using
a Speed-Vac system (ThermoSavant, AES2010) before hy-
bridization.
Microarray hybridization and scanning
To hybridize the arrays, purified and labeled cDNA targets
were dissolved in 100 µl total volume of ExpressHyb solu-
tion (Clontech, Palo Alto, CA) containing 8 µg of
polydA40–60 (Amersham Pharmacia), 2 µg of yeast tRNA
(Gibco-BRL), 10 µg of human Cot I DNA (Gibco-BRL).
The mixture was heated to 95°C for 10 min, then applied
to the slides and covered by a coverslip. Hybridization was
carried out at 60°C for 14–16 hours in a moisturized box
in an incubator. Slides were washed at 37°C in 1× SSC (3
M sodium chloride, 0.3 M sodium citrate), 0.01% SDS,
0.2× SSC, 0.01% SDS, and twice in 0.1× SSC sequentially
for 2 min each. Hybridized arrays were scanned at 10-µm
resolution on a LSIV scanner (Genomic Solution, Ann Ar-
bor, MI).
Data quantification
Scanned microarray images (16-bit TIFF formatted files)
were quantified with ArrayVision™ (Imaging Research,
Inc., St. Catherine's, Ontario, Canada), and values were re-
corded for spot intensity, local background intensity, and
signal-to-noise (S/N) ratio. Spot intensity was computed
as the integrated optical density or volume in a fixed-size
circle; background intensity was computed as the median
pixel value of four diamond-shaped regions at the corners
of each spot. Background-corrected intensity was comput-
ed by subtracting local background from spot intensity.
The S/N ratio was computed by dividing the background-
corrected intensity by the standard deviation (SD) of the
background pixels.
Data normalization
Data from all microarrays was imported into S-plus™ (In-
sightful Corp., Seattle, WA), for further analysis. For each
microarray, the background-corrected spot intensities
were normalized by setting the 75th percentile equal to
1000. This procedure brings the median log ratio between
channels close to 1 for expressed spots, and it also permits
us to compare individual channels across arrays. After
normalization, any spot whose normalized intensity re-
mained below the threshold value of 150 was considered
to be undetectable, and its value was replaced by the
threshold value. In our arrays, a normalized value of 150
corresponds roughly to a spot whose S/N ratio equals 1,
and thus any spot whose background-corrected intensity
falls below this threshold cannot be reliably distinguished
from background noise. Finally the background-correct-
ed, normalized signal intensities were log-transformed
(base two) for further analysis.Page 7 of 8
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The sequencing verified cDNAs used to print the microar-
rays were used as templates and the probes were labeled
using Rediprime II Random Prime Labeling System (Am-
ersham). For northern blotting, 20 µg of total RNA was
electrophorized on a denaturing agarose gel, transferred
to nylon membrane, and hybridized to 33P labeled cDNA
probes as described previously [11].
Western blotting analysis
For western blotting, 40 µg of total cellular protein was
run on a SDS-PAGE gel, transferred to a nylon membrane,
and incubated with IGFBP2 antibody (Santa Cruz Bio-
technology, Inc.) following the procedure as described
[11].
Immunohistochemistry assay
Cell pellets were first embedded to paraffin block and sec-
tions cut and mounted onto microscope slides. The pres-
ence of S100, GFAP, and IGFBP2 antigens was detected by
their antibodies following standard immunohistochemis-
try procedures [11].
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